BMRN Earnings Biomarin Pharmaceutical Inc
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–60 of 60
| Q3 2026 | 2026-09-30 | -0.63 | 2026-11-03 | 10-Q |
| Q2 2026 | 2026-06-30 | 0.23 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | 0.54 | 2026-05-05 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -0.22 | 2026-02-26 | 10-K |
| FY 2025 | 2025-12-31 | 1.80 | 2026-02-26 | 10-K |
| Q3 2025 | 2025-09-30 | -0.16 | 2025-10-28 | 10-Q |
| Q2 2025 | 2025-06-30 | 1.23 | 2025-08-05 | 10-Q |
| Q1 2025 | 2025-03-31 | 0.95 | 2025-05-02 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | 0.65 | 2025-02-24 | 10-K |
| FY 2024 | 2024-12-31 | 2.21 | 2025-02-24 | 10-K |
| Q3 2024 | 2024-09-30 | 0.55 | 2024-10-31 | 10-Q |
| Q2 2024 | 2024-06-30 | 0.55 | 2024-08-05 | 10-Q |
| Q1 2024 | 2024-03-31 | 0.46 | 2024-04-26 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | 0.10 | 2024-02-26 | 10-K |
| FY 2023 | 2023-12-31 | 0.87 | 2024-02-26 | 10-K |
| Q3 2023 | 2023-09-30 | 0.21 | 2023-11-02 | 10-Q |
| Q2 2023 | 2023-06-30 | 0.29 | 2023-08-02 | 10-Q |
| Q1 2023 | 2023-03-31 | 0.27 | 2023-04-28 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | 0.01 | 2023-02-27 | 10-K |
| FY 2022 | 2022-12-31 | 0.75 | 2023-02-27 | 10-K |
| Q3 2022 | 2022-09-30 | -0.04 | 2022-10-28 | 10-Q |
| Q2 2022 | 2022-06-30 | 0.15 | 2022-08-04 | 10-Q |
| Q1 2022 | 2022-03-31 | 0.63 | 2022-04-29 | 10-Q |
| Q4 2021 (derived) | 2021-12-31 | -0.31 | 2022-02-25 | 10-K |
| FY 2021 | 2021-12-31 | -0.35 | 2022-02-25 | 10-K |
| Q3 2021 | 2021-09-30 | -0.20 | 2021-10-29 | 10-Q |
| Q2 2021 | 2021-06-30 | 0.07 | 2021-07-30 | 10-Q |
| Q1 2021 | 2021-03-31 | 0.09 | 2021-04-30 | 10-Q |
| Q4 2020 (derived) | 2020-12-31 | 0.21 | 2021-02-26 | 10-K |
| FY 2020 | 2020-12-31 | 4.50 | 2021-02-26 | 10-K |
| Q3 2020 | 2020-09-30 | 4.01 | 2020-11-06 | 10-Q |
| Q2 2020 | 2020-06-30 | -0.16 | 2020-08-05 | 10-Q |
| Q1 2020 | 2020-03-31 | 0.44 | 2020-05-01 | 10-Q |
| Q4 2019 (derived) | 2019-12-31 | 0.10 | 2020-02-27 | 10-K |
| FY 2019 | 2019-12-31 | -0.13 | 2020-02-27 | 10-K |
| Q3 2019 | 2019-09-30 | 0.30 | 2019-10-29 | 10-Q |
| Q2 2019 | 2019-06-30 | -0.21 | — | — |
| Q1 2019 | 2019-03-31 | -0.32 | 2019-04-29 | 10-Q |
| FY 2018 | 2018-12-31 | -0.44 | 2019-02-28 | 10-K |
| Q3 2018 | 2018-09-30 | -0.07 | — | — |
| Q1 2018 | 2018-03-31 | -0.26 | 2018-04-27 | 10-Q |
| FY 2017 | 2017-12-31 | -0.67 | 2018-02-26 | 10-K |
| Q3 2017 | 2017-09-30 | -0.07 | 2017-10-31 | 10-Q |
| Q1 2017 | 2017-03-31 | -0.09 | — | — |
| FY 2016 | 2016-12-31 | -3.81 | 2017-02-27 | 10-K |
| Q3 2016 | 2016-09-30 | -0.22 | 2016-11-03 | 10-Q |
| Q4 2015 (derived) | 2015-12-31 | 0.47 | — | — |
| FY 2015 | 2015-12-31 | -1.07 | — | — |
| Q3 2015 | 2015-09-30 | -0.60 | 2015-11-02 | 10-Q |
| Q2 2015 | 2015-06-30 | -0.51 | 2015-08-05 | 10-Q |
| Q1 2015 | 2015-03-31 | -0.43 | 2015-05-05 | 10-Q |
| Q4 2014 (derived) | 2014-12-31 | -0.47 | — | — |
| FY 2014 | 2014-12-31 | -0.92 | — | — |
| Q3 2014 | 2014-09-30 | 0.05 | 2014-10-28 | 10-Q |
| Q2 2014 | 2014-06-30 | -0.23 | 2014-07-31 | 10-Q |
| Q1 2014 | 2014-03-31 | -0.27 | 2014-05-02 | 10-Q |
| Q3 2013 | 2013-09-30 | -0.38 | — | — |
| Q2 2013 | 2013-06-30 | -0.16 | 2013-07-29 | 10-Q |
| Q1 2013 | 2013-03-31 | -0.31 | — | — |
| FY 2012 | 2012-12-31 | -0.95 | 2013-02-26 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.